DX308 is a potent, selective dual CYP26A1/B1 inhibitor and retinoic acid metabolism blocking agent.
DX308 does not interact with off‐target nuclear receptors or CYP450s, is not genotoxic, and is stable in skin, despite vigorous hepatic metabolism.
Topical DX308 induces comedolysis and epidermal thickening without apparent adverse effects in vivo.
DX308 shows potent modulation of retinoid‐responsive genes by DX308 in both healthy and keratinization disorder keratinocytes (KCs).
DX308 may present an improved therapeutic alternative for the treatment of keratinization disorders and other retinoid‐responsive skin ailments.
